Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03971617 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
A Phase 2 study, sponsored by Stony Brook University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03971617 is a Phase 2 study that was terminated before completion, run by Stony Brook University. The registered enrollment target is 2 participants.
The verdict
NCT03971617, a Phase 2 study, was terminated before completion, sponsored by Stony Brook University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with early-stage Parkinson's Disease. The medication will be administered orally as 8 ounces of hydrogen-enriched drinking water twice a day over the course of one year.
Interventions
- DRUG Placebo oral tablet
- DRUG Hydrogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2021-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03971617
The ClinicalTrials.gov registry entry for NCT03971617 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT03971617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03971617 about?
NCT03971617 is a clinical study titled "Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease". This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with early-stage Parkinson's Disease. The medication will be administered orally as 8 ounces of hydrogen-enriched drinking water ...
What is the current status of trial NCT03971617?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2019-05-29. Estimated completion is 2021-04-29.
What interventions are being tested in trial NCT03971617?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydrogen (DRUG).
Who is sponsoring clinical trial NCT03971617?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.